Skip to main content
    O

    OmniAb Inc. (OABI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.89
    -0.02 (-0.41%)

    Market Cap: $716.17M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    OmniAb Inc. (OABI) Earnings: Report Dates and Results

    Updated Oct 30, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    OmniAb (OABI) is expected to report earnings on Mar 2, 2027. In the quarter ended Sep 30, 2026, OmniAb reported EPS of -$0.12, in line with the -$0.12 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    38%(6/16)
    Avg Surprise
    +18.60%

    Upcoming Estimates

    Reports Mar 2, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.12
    Range-$0.13 - -$0.12
    9 analysts
    Revenue Consensus
    $5.31M
    Range$3.63M - $6.89M
    9 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.10
    Range-$0.12 - -$0.07
    2 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.08-18.8%
    60d ago-$0.10+5.0%
    30d ago-$0.10+5.0%
    7d ago-$0.10+5.0%
    Current-$0.10
    Revenue Consensus
    $7.38M
    Range$5.03M - $9.73M
    2 analysts

    Next Report

    OABI has an expected report date of Mar 2, 2027.

    OABI Earnings Call

    The latest OABI earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 16 quarters below that had an estimate, OABI beat 6, missed 6 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $3.99M, up 78.1% from $2.24M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.12-$0.12-$0.14 - -$0.120.00%In lineN/A41 up, 3 downOct 30, 2026$3.99M
    Jun 30, 2026-$0.05-$0.11N/A+54.55%BeatN/A40 up, 3 downAug 6, 2026$13.41M
    Mar 31, 2026-$0.06-$0.10-$0.11 - -$0.09+40.00%BeatN/A31 up, 0 downMay 7, 2026$14.43M
    Dec 31, 2025-$0.11-$0.09-$0.11 - -$0.07-25.71%MissN/A41 up, 0 downMar 4, 2026$8.38M
    Sep 30, 2025-$0.14-$0.14-$0.15 - -$0.120.00%In lineN/A51 up, 1 downNov 4, 2025$2.24M
    Jun 30, 2025-$0.15-$0.15-$0.19 - -$0.140.00%In lineN/A62 up, 0 downAug 6, 2025$3.90M
    Mar 31, 2025-$0.17-$0.17-$0.19 - -$0.150.00%In lineN/A60 up, 1 downMay 8, 2025$4.15M
    Dec 31, 2024-$0.12-$0.10-$0.11 - -$0.08-24.10%MissN/A62 up, 1 downMar 18, 2025$10.80M
    Sep 30, 2024-$0.16-$0.14-$0.16 - -$0.12-14.29%MissN/A80 up, 0 downNov 12, 2024$4.17M
    Jun 30, 2024-$0.13-$0.17-$0.20 - -$0.13+23.53%BeatN/A70 up, 0 downAug 8, 2024$7.61M
    Mar 31, 2024-$0.19-$0.16-$0.20 - -$0.12-18.75%MissN/A80 up, 0 downMay 9, 2024$3.80M
    Dec 31, 2023-$0.14-$0.15-$0.20 - -$0.11+6.67%Beat-300.0%80 up, 0 downMar 20, 2024$4.82M
    Sep 30, 2023-$0.16-$0.13-$0.16 - -$0.11-23.08%MissN/A70 up, 1 downNov 9, 2023$5.48M
    Jun 30, 2023-$0.15-$0.12-$0.15 - -$0.05-25.00%MissN/A70 up, 0 downAug 10, 2023$6.95M
    Mar 31, 2023-$0.06-$0.13-$0.15 - $0.20+53.85%BeatN/A70 up, 0 downMay 11, 2023$16.92M
    Dec 31, 2022$0.07$0.02-$0.16 - $0.09+250.00%BeatN/A50 up, 2 downMar 30, 2023$35.34M
    Sep 30, 2022-$0.09N/AN/AN/AN/AN/AN/AN/ANov 10, 2022$6.91M
    Jun 30, 2022-$0.06N/AN/AN/AN/AN/AN/AN/AAug 12, 2022$7.20M
    Mar 31, 2022-$0.16N/AN/AN/AN/AN/AN/AN/AMay 20, 2022$9.62M
    Dec 31, 2021-$0.01N/AN/AN/AN/AN/AN/AN/AMar 25, 2022$15.28M
    Sep 30, 2021-$0.01N/AN/AN/AN/AN/AN/AN/ANov 10, 2021N/A
    Jun 30, 2021Not reportedN/AN/AN/ANot reportedN/AN/AN/ASep 23, 2021N/A
    Mar 31, 2021Not reportedN/AN/AN/ANot reportedN/AN/AN/AJun 29, 2021$6.60M
    Last 23 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.57, after -$0.60 the year before. It was -$0.02 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.57N/A
    Dec 31, 2024-$0.60N/A
    Dec 31, 2023-$0.51N/A
    Dec 31, 2022-$0.24N/A
    Dec 31, 2021-$0.02N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,500 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,48511
    2026Q2Jun 30, 20265,8749
    2026Q1Mar 31, 20266,4179
    2025Q4Dec 31, 20255,99810
    2025Q3Sep 30, 20255,6718
    2025Q2Jun 30, 20254,9937
    2025Q1Mar 31, 20254,7158
    2024Q4Dec 31, 20246,5466

    2026Q3 Earnings Call

    Opening remarks

    Kurt Gustafson Chief Financial Officer Thank you, operator, and good morning, everyone. This is Kurt Gustafson, OmniAb's Chief Financial Officer, and thank you all for joining our third quarter 2026 financial results conference call. There are slides to accompany today's prepared remarks, and they're available in the Investors section of our website at omniab.com. Before we begin, I'd like to remind listeners that comments made during this call by OmniAb's management will include forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from any of the anticipated results. These forward-looking statements are qualified by the cautionary statements contained in today's press release and our SEC filings. Importantly, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast today, October 30, 2026. Except as required by law, OmniAb undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Joining me this morning is Matt Foehr, OmniAb's President and CEO, and Amechi Nwachuku, our Chief Operating Officer. During today's call, Matt is going to cover some highlights. Amechi will provide an update on our xPloration program, and I'll go through our financial results and guidance, and then we'll open up the call to questions. And with that, let me turn the call over to Matt.

    Matthew Foehr President and CEO Thanks, Kurt. Good morning, everyone, and thanks for joining our third quarter call. I'll start now on Slide number 4, which includes some highlights from the third quarter. Our business here at OmniAb has been designed to benefit from diversified, long-term, and durable revenue streams. We continued to drive strong performance in the third quarter as our highly differentiated technology platforms are facilitating growth in partnerships and progression of programs. We have been and continue to be very active from a licensing perspective and announced a major new deal in the quarter with Eli Lilly for a novel ion channel program. We were really pleased to enter into this important new relationship with Lilly, as they're obviously focused on delivering medicines to address major unmet medical needs, and our differentiated expertise and established technologies that specifically relate to ion channels are well positioned to help facilitate that and drive this new discovery program forward. Under the terms of that license deal, we received an upfront payment and are eligible to receive up to $370 million in research, development, and commercial milestone payments, as well as potential tiered royalties on global net sales. In Q3, we saw increased utilization of our differentiated technologies within our growing ecosystem of partners.

    Frequently Asked Questions About OABI

    When is OmniAb's next earnings date?

    OmniAb's next earnings report is expected for Mar 2, 2027.

    Did OABI beat earnings estimates last quarter?

    OmniAb reported EPS of -$0.12 for the quarter ended Sep 30, 2026, in line with the -$0.12 estimate.

    What EPS do analysts expect from OABI next quarter?

    The consensus EPS estimate for OmniAb for the quarter ending Dec 31, 2026 is -$0.12 from 9 analysts, with estimates from -$0.13 to -$0.12.

    How often does OABI beat earnings estimates?

    OmniAb beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of +5.59%.